Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day
16 nov. 2017 16h45 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights
02 nov. 2017 16h01 HE
|
Voyager Therapeutics, Inc.
VY-AADC for advanced Parkinson’s disease on track for start of global, pivotal phase 2-3 program Integration of novel capsid and delivery optimization efforts expected to result in two IND filings...